Cynthia Siu

TL;DR: The authors present consensus guidelines that operationalize criteria for determining and reporting treatment resistance, adequate treatment, and treatment response, providing a benchmark for research and clinical translation in schizophrenia.

TL;DR: Evaluated weight effects in patients receiving standard doses of amisulpride, haloperidol, olanzapine, risperidone, ziprasid one, and placebo confirm significant differences in long-term weight effects among atypical antipsychotics, consistent with findings from prior meta-analysis of antipsychotic-induced weight gain.

TL;DR: In the context of a 29-site antipsychotic trial in stable outpatients with schizophrenia, the MCCB is sensitive to cognitive deficits in all domains, demonstrates excellent test-retest reliability and small practice effects, and is strongly correlated with a leading measure of functional capacity.

TL;DR: During 6 weeks' treatment, ziprasidone and olanzapine demonstrated comparable antipsychotic efficacy and both agents were well tolerated.

TL;DR: This study identified important patient characteristics and trial design factors affecting the level of placebo response and hence the likelihood of detecting efficacy signals in randomized controlled trials.